Progestogens and venous thromboembolism in menopausal women: an updated oral versus transdermal estrogen meta-analysis

@article{Scarabin2018ProgestogensAV,
  title={Progestogens and venous thromboembolism in menopausal women: an updated oral versus transdermal estrogen meta-analysis},
  author={P. Scarabin},
  journal={Climacteric},
  year={2018},
  volume={21},
  pages={341 - 345}
}
Abstract Postmenopausal hormone therapy (HT) is a modifiable risk factor for venous thromboembolism (VTE). While the route of estrogen administration is now well recognized as an important determinant of VTE risk, there is also increasing evidence that progestogens may modulate the estrogen-related VTE risk. This review updates previous meta-analyses of VTE risk in HT users, focusing on the route of estrogen administration, hormonal regimen and progestogen type. Among women using estrogen-only… Expand
Update on Menopausal Hormone Therapy for Fracture Prevention
Progesterone Is Important for Transgender Women’s Therapy—Applying Evidence for the Benefits of Progesterone in Ciswomen
  • J. Prior
  • Medicine
  • The Journal of clinical endocrinology and metabolism
  • 2019
The pharmacodynamics and safety of progesterone.
  • P. Piette
  • Medicine
  • Best practice & research. Clinical obstetrics & gynaecology
  • 2020
Making choices at menopause.
...
1
2
...

References

SHOWING 1-10 OF 45 REFERENCES
Hormone therapy and venous thromboembolism among postmenopausal women.
Hormones and venous thromboembolism among postmenopausal women
  • P. Scarabin
  • Medicine
  • Climacteric : the journal of the International Menopause Society
  • 2014
Estrogen and progestogen effect on venous thromboembolism in menopausal women
  • D. Archer, E. Oger
  • Medicine
  • Climacteric : the journal of the International Menopause Society
  • 2012
...
1
2
3
4
5
...